Zhengye Biotechnology Holding (ZYBT) Inventory Average (2024 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Inventory Average of $6.5 million for Q4 2025, down 19.78% year-over-year from $8.1 million in Q4 2024, and down 16.58% quarter-over-quarter from $7.8 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Inventory Average (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Inventory Average for 2 consecutive years, with $6.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Inventory Average fell 19.78% year-over-year to $6.5 million; the TTM figure through Dec 2025 stood at $6.5 million (down 19.78% YoY), while the FY2025 annual figure was $6.8 million, down 15.53% from the prior year.
- Inventory Average retreated to $6.5 million in Q4 2025 per ZYBT's latest filing, from $7.8 million in the prior quarter.
- Across five years, Inventory Average topped out at $8.1 million in Q4 2024 and bottomed at $6.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 1.41 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.20 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.56 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 8.99 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 186.05 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 3.93 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.35 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.74 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 824.00 Mn |
| 10 | Zhengye Biotechnology Holding | 86.79 Mn | 79.48 Mn | - | 6.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.50 Mn |
| Jun 30, 2025 | 7.79 Mn |
| Dec 31, 2024 | 8.10 Mn |